EUNew treatments and approvals
Leriglitazone approved in the EU for boys aged 2-12 with cerebral adrenoleukodystrophy
A decision by a medicines regulator (FDA, European Commission, etc.). The regulator has reviewed the clinical studies behind the drug. For accelerated or conditional approvals, the lasting benefit is still being confirmed.
In Europe, leriglitazone, taken by mouth, was authorized for cerebral adrenoleukodystrophy. The approval covers boys aged 2-12 who have no contrast-enhancing lesion on brain MRI. The child's neurological function score must also be 0 or 1. The authorization was granted under exceptional circumstances; the company is required to submit long-term efficacy data.
What does it mean for patients and families?
This approval is for a small group of patients at an early stage. Access in Türkiye depends on TİTCK (Turkish Medicines and Medical Devices Agency) and SGK (Social Security Institution) processes. Other options, such as transplantation, should be discussed with the doctor.
Source
Avrupa İlaç Ajansı (EMA) · source page
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: X-linked adrenoleukodystrophy (X-ALD)
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.